Clinical Trials

Genentech ML42439 (myTACTIC) ALK

myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: ArmC: Alectinib in patients with ALK rearrangement-positive tumors

NCT04632992

Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,

Stage 4

Metastatic/Palliative

Any line

Alectinib

ALK and RET inhibitor

Axel Grothey, MD

Genentech, Inc.

Phase 2

Open to Enrollment

• Histologically or cytologically confirmed advanced unresectable or metastatic solid malignancy
• Positive biomarker results from a CLIA certified lab, either tissue or blood sample
• Not Non-small cell lung cancer (NO NSCLC)
• ALK gene fusion positivety defined as a 3' AALK fusion with a protein coding 5' gene fusion partner, predicted to be in frame with an intact kinase domain
• ECOG PS 0-2
• No symptomatic CNS metastases
• No known HIV/HBV/HCV
• No other malignancy within 3 years of study
• No prior treatment with crizotinib

• Primary-
  • ORR
• Secondary
  • PFS
  • oR
  • OS
  • PFS at various time poitns
  • DCR
  • Safety

_

_

ALK rearrangement/fusion in any malignancy except not NSCLC

No